Diabetes Treatment

SureNano Science Featured in BioMedWire Editorial Highlighting GLP-1 Innovation

SureNano Science Featured in BioMedWire Editorial Highlighting GLP-1 Innovation

SureNano Science Ltd. was featured in a BioMedWire editorial discussing its subsidiary GlucaPharm Inc. and its GEP-44 triple agonist peptide, which aims to improve obesity and diabetes treatment with better tolerability and potential non-injectable delivery.

May 14, 2026
SureNano Science Advances GLP-1 Drug Candidate Toward Clinical Trials, Expands Investor Outreach

SureNano Science Advances GLP-1 Drug Candidate Toward Clinical Trials, Expands Investor Outreach

SureNano Science Ltd. is moving its lead obesity and diabetes drug GEP-44 into FDA IND-enabling studies with LabCorp while broadening investor communications through a partnership with Investor Brand Network.

April 24, 2026